Oncolytics Biotech庐 Regains Compliance with Nasdaq Trading Rules
Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy oncology company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received formal confirmation from Nasdaq's Listing Qualifications Department on July 22, 2025.
After falling below the required $1.00 minimum bid price in February 2025, ONCY has maintained a closing bid price at or above $1.00 for 10 consecutive business days from July 8 through July 21, 2025. The company is now fully compliant with all Nasdaq listing standards and will continue trading on the Nasdaq Capital Market.
Oncolytics Biotech (NASDAQ: ONCY), un'azienda di immunoterapia oncologica in fase clinica, ha riconquistato con successo la conformit脿 al requisito minimo del prezzo di offerta di Nasdaq. La societ脿 ha ricevuto la conferma ufficiale dal Dipartimento di Qualifica delle Quotazioni di Nasdaq il 22 luglio 2025.
Dopo essere scesa sotto il requisito minimo di $1,00 a febbraio 2025, ONCY ha mantenuto un prezzo di chiusura pari o superiore a $1,00 per 10 giorni lavorativi consecutivi dal 8 al 21 luglio 2025. Ora la societ脿 猫 pienamente conforme a tutti gli standard di quotazione Nasdaq e continuer脿 a essere negoziata sul Nasdaq Capital Market.
Oncolytics Biotech (NASDAQ: ONCY), una empresa de inmunoterapia oncol贸gica en etapa cl铆nica, ha recuperado con 茅xito el cumplimiento del requisito m铆nimo de precio de oferta de Nasdaq. La compa帽铆a recibi贸 la confirmaci贸n formal del Departamento de Calificaci贸n de Listados de Nasdaq el 22 de julio de 2025.
Despu茅s de caer por debajo del requisito m铆nimo de $1.00 en febrero de 2025, ONCY mantuvo un precio de cierre igual o superior a $1.00 durante 10 d铆as h谩biles consecutivos desde el 8 hasta el 21 de julio de 2025. La empresa ahora cumple plenamente con todos los est谩ndares de listado de Nasdaq y continuar谩 cotizando en el Nasdaq Capital Market.
Oncolytics Biotech (NASDAQ: ONCY)電� 鞛勳儊 雼硠鞚� 氅挫棴頃晹鞝� 須岇偓搿�, 雮橃姢雼レ潣 斓滌唽 鞛呾鞍 臧�瓴� 鞖旉贝鞚� 靹标车鞝侅溂搿� 於╈”頃橃榾鞀惦媹雼�. 須岇偓電� 2025雲� 7鞗� 22鞚� 雮橃姢雼� 靸侅灔 鞛愱博 攵�靹滊攵�韯� 瓿奠嫕 頇曥澑鞚� 氚涭晿鞀惦媹雼�.
2025雲� 2鞗旍棎 頃勳殧頃� $1.00 斓滌唽 鞛呾鞍 臧�瓴� 鞎勲灅搿� 霒柎歆� 頉�, ONCY電� 2025雲� 7鞗� 8鞚茧秬韯� 7鞗� 21鞚缄箤歆� 10瓯半灅鞚� 鞐办啀鞙茧 膦呹皜臧� $1.00 鞚挫儊鞚� 鞙犾頃橃榾鞀惦媹雼�. 須岇偓電� 鞚挫牅 氇摖 雮橃姢雼� 靸侅灔 旮办鞚� 鞕勳爠頌� 於╈”頃橂┌ 雮橃姢雼� 旌愴敿韯� 毵堨紦鞐愳劀 瓿勳啀 瓯半灅霅� 瓴冹瀰雼堧嫟.
Oncolytics Biotech (NASDAQ : ONCY), une soci茅t茅 d'immunoth茅rapie oncologique en phase clinique, a r茅ussi 脿 se conformer 脿 nouveau 脿 l'exigence minimale du prix d'offre de Nasdaq. La soci茅t茅 a re莽u la confirmation officielle du D茅partement des Qualifications de Cotation de Nasdaq le 22 juillet 2025.
Apr猫s 锚tre tomb茅e en dessous du prix d'offre minimum de 1,00 $ en f茅vrier 2025, ONCY a maintenu un cours de cl么ture 茅gal ou sup茅rieur 脿 1,00 $ pendant 10 jours ouvrables cons茅cutifs du 8 au 21 juillet 2025. La soci茅t茅 est d茅sormais pleinement conforme 脿 toutes les normes de cotation Nasdaq et continuera 脿 锚tre n茅goci茅e sur le Nasdaq Capital Market.
Oncolytics Biotech (NASDAQ: ONCY), ein klinisch fortgeschrittenes Immuntherapie-Onkologieunternehmen, hat erfolgreich die Einhaltung der Mindestgebotspreisvorgabe der Nasdaq wiedererlangt. Das Unternehmen erhielt am 22. Juli 2025 eine offizielle Best盲tigung von der Nasdaq Listing Qualifications Abteilung.
Nachdem der Kurs im Februar 2025 unter den erforderlichen Mindestgebotspreis von $1,00 gefallen war, hielt ONCY den Schlusskurs f眉r 10 aufeinanderfolgende Handelstage vom 8. bis 21. Juli 2025 bei $1,00 oder h枚her. Das Unternehmen erf眉llt nun alle Nasdaq-Listenstandards vollst盲ndig und wird weiterhin am Nasdaq Capital Market gehandelt.
- Regained compliance with Nasdaq listing requirements
- Stock price maintained above $1.00 for required period
- Continues trading on Nasdaq Capital Market without interruption
- Previously failed to meet minimum bid price requirement
- Stock traded below $1.00 for extended period earlier in 2025
As previously announced, the Company was notified by Nasdaq on February 13, 2025, that the Company's common shares failed to maintain a minimum bid price of
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype 鈥� turning "cold" tumors "hot" 鈥� through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit:听听or follow the company on social media on 听and on X @.
Company Contact听
Jon Patton
Director of IR & Communication
[email protected]听
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]听
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
[email protected]听
Logo -
View original content to download multimedia:
SOURCE Oncolytics Biotech庐 Inc.
FAQ
Has ONCY stock regained Nasdaq compliance in 2025?
What is the minimum stock price requirement for Nasdaq listing that ONCY had to meet?
When did Oncolytics Biotech receive the Nasdaq deficiency notice?
Will ONCY continue trading on Nasdaq after regaining compliance?
